Drug updated on 4/17/2024
| Dosage Form | Tablet (oral: 2.5 mg, 5 mg, 10 mg, 20 mg) |
| Drug Class | Phosphodiesterase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of erectile dysfunction (ED).
- Indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
- Indicated for or the treatment of ED and the signs and symptoms of BPH (ED/BPH).
Summary
- Tadalafil (Cialis) is indicated for the treatment of erectile dysfunction, benign prostatic hyperplasia, and a combination of both. It has shown effectiveness in treating these conditions either alone or in combination with tamsulosin.
- The information was derived from nine systematic reviews/meta-analyses focused on the use of tadalafil and its comparison to other drugs across various indications.
- Compared to sildenafil in esophageal motility disorders, PDE-5 inhibitors like tadalafil are suggested to have beneficial effects, although specific comparative safety data between them were not provided.
- In male lower urinary tract symptoms (LUTS), with or without erectile dysfunction (ED), tadalafil showed a good efficacy profile as it had lower discontinuation rates due to lack of efficacy. Its rate of discontinuation due to adverse events was also relatively low, indicating that it's well tolerated by patients.
- When compared against all PDE5 inhibitors used for men with ED, tadalafil, along with sildenafil, were highlighted for their efficacy. However, at recommended doses, tadalafil may offer an advantageous safety profile over others, which noted side effects at higher doses.
- Treatment using tadalafil significantly improved sperm concentration, motility, and morphology, thus showing promising results towards managing male infertility, but explicit safety data relative to this indication was not provided.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cialis (tadalafil) Prescribing Information. | 2023 | Lilly USA, LLC., Indianapolis, IN |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition). | 2021 | Military Medical Research |